-
JHO: Dara-DCEP treatment with extramedullary lesions RRMM, ORR 67.7%, PFS 5 months
Time of Update: 2022-11-04
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
-
【JHO】Chinese expert consensus on clinical practice of primary CNS lymphoma based on evidence
Time of Update: 2022-11-04
At baseline and follow-up, evaluation of neurocognitive function in patients with PCNSL is recommended Suggested flow chart of diagnosis and treatment ReferencesTong Chen, Yuanbo Liu, Yang Wang,et al.
-
Professor Wu Depei New stage, new concept, new pattern - the 2022 version of the guidelines leads a new era of TTP diagnosis and treatment
Time of Update: 2022-11-01
Thrombotic thrombocytopenic purpura (TTP) is a rare, severe thrombotic microangiopathy characterized by moderate to severe thrombocytopenia, microangiopathic hemolytic anemia (MAHA), ischemia, and ext
-
The road is far away, and the road is within reach——CSCO Autologous Transplantation Working Group 2022 Tour (Northeast Three Provinces) was a complete success
Time of Update: 2022-11-01
On October 16, 2022, the CSCO Autologous Transplantation Working Group 2022 Tour (Northeast Three Provinces) hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee,
-
Whole genome sequencing reveals potentially complex genomic features in lymphoma patients who have failed CD19 CAR-T cell therapy
Time of Update: 2022-11-01
Table 102Clinical features of the study resultsA total of 49 LBCL patients were included in this review: 40 were new-onset DLBCL, 8 were converted follicular lymphoma (FL), and 1 was transformed chronic lymphoblastic leukemia (CLL).
-
Update on the results of the Phase II trial of Camidanlumab Tesirine in relapsed/refractory classic Hodgkin lymphoma: both overall and complete response rates have increased!
Time of Update: 2022-11-01
conducted a phase II trial to further explore the efficacy and safety of Cami monotherapy in R/R cHL, and presented the results at the 2021 ICML Congress (overall response rate [ORR] 66.
-
2022 SHS Miao Aiming Director: Focus on prevention, traceability, and curative effect, and the treatment level of aplastic anemia will be raised to a higher level
Time of Update: 2022-11-01
Yimaitong: What are the treatment progress worth paying attention to in the field of AA in recent years?Director MiaoInteresting therapeutic advances in the field of AA include two aspects, one of which is new drugs, such as TPO receptor agonists, which can be combined with immunosuppressive therapy to improve the hematological response rate of AA patients.
-
Professor Zhou Daobin and Professor Li Zhiming: Searching for sand, Pola brings new treatment options to elderly patients with frailty/intolerance in DLBCL
Time of Update: 2022-11-01
GuideEvery unknown world is opened with pioneers who bravely foresee; Every journey of sneaking through the dark night is fearlessly led by the lighter. The series of reports "Solving the Problem - Un
-
Micro Classroom No. 15 Professor Xu Shuangnian: Progress in the treatment of AL amyloidosis
Time of Update: 2022-11-01
8 monthsFig. 3 Cardiac and renal response rates at median follow-up of 6 and 18 monthsAlthough the ANDROMEDA study has confirmed the good efficacy of daratumumab in the treatment of AL amyloidosis, the prognosis of AL amyloidosis patients with advanced cardiac involvement is extremely poor, and its benefit from daratumab treatment has also attracted much attention.
-
Blood-friendly new students live up to the new chapter of Shaohuapu and look forward to the future, and the Hemophilia Frontier Progress Tour (Anhui Station) ended successfully
Time of Update: 2022-11-01
In recent years, the continuous advent of innovative drugs or therapies has increasingly met the diversified clinical treatment needs of patients with hemophilia A. However, individual patient variabi
-
Let the world hear the voice of Chinese scholars: Professor Zhang Yonghong led the team to break through innovation and promote the continuous development of the field of refractory relapsed lymphoma in children
Time of Update: 2022-11-01
*For medical professionals onlyOn October 20-23, 2022, the 7th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma was held in New York, USA. Recent scientific
-
Fei Fan Blood Cloud Classroom October Myeloma Literature Intensive Reading Workshop
Time of Update: 2022-11-01
The enrolled patients were stratified according to IMWG 20/2/20 criteria, and the proportion of low, intermediate and high-risk patients was 40%, 40%, and 20%, respectively, and none of them reached the median TTP, and the estimated disease progression rates at 2 years were 2%, 27%, and 44%, respectively.
-
Lymphoma Interview Professor Zhou Keshu: Targeting the first opportunity, making precise efforts, and innovating PI3K inhibitors bring new hope to FL patients!
Time of Update: 2022-11-01
1 months, p4。The GADOLIN study, a global multicenter phase III clinical trial of obinutuzumab, enrolled patients with indolent lymphoma (including FL) who relapsed and refractory to rituximab who received bendamustine monotherapy (group B) and obinutuzumab plus bendamustine (GB group), respectively, and the results of the FL subgroup showed that the progression-free survival (PFS) (25.
-
Expert ConsensusProfessor Wu Depei, Professor Hu Yu and Professor Li Juan: The Expert Consensus on the Clinical Application of Selinisosol in Multiple Myeloma (2022) was officially released, helping to standardize the use of Selinisole!
Time of Update: 2022-11-01
Selinisol is the world's first potent, oral nuclear output protein inhibitor with a unique mechanism of action and multiple signaling pathways, which can synergistically enhance the anti-tumor activit
-
Case expert evaluation Professor Liu Qiqi: Breaking through the clouds, girutinib helps patients with relapsed FLT3 mutation AML transplantation to benefit, and the whole process of FLT3 mutation AML is managed like a tiger
Time of Update: 2022-11-01
The patient in this case was AML with FLT3-ITD mutation, and the MRD was negative after chemotherapy combined with sorafenib treatment before transplantation, and the intermittent sorafenib maintenance therapy after transplantation still had post-transplant recurrence, and was induced and consolidated by giretinib combined with chemotherapy, and hiratinib survived without disease after maintenance therapy.
-
【Heavy】6 essentials of perioperative comprehensive management of hip and knee replacement in hemophilia
Time of Update: 2022-11-01
Recently, the Guidelines for the Perioperative Management of Hip and Knee Replacement in Hemophilic Osteoarthropathy1, jointly compiled by the Joint Surgery Group of the Orthopedic Branch of the Chine
-
Unswerving, lighting up the hope of cure - CSCO Autologous Transplantation Working Group 2022 Lymphoma Tour (Hunan Station) ended successfully
Time of Update: 2022-11-01
Hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee, CSCO Leukemia Expert Committee, CSCO Autologous Hematopoietic Stem Cell Transplantation (ASCT) Working Group,
-
Zhong "Ai" accurately targets the future Professor Shen Zhixiang: Precision first, target leading, from the latest progress of AML to see the new trend of AML precision diagnosis and treatment
Time of Update: 2022-11-01
Poke "Read Original" to see moreEditor: May Review: Janet Typesetting: moly Execution: moly This platform aims to deliver more medical information to healthcare professionals.
Poke "Read Original" to see moreEditor: May Review: Janet Typesetting: moly Execution: moly This platform aims to deliver more medical information to healthcare professionals.
-
What is the efficacy of CD20 CAR-T as a salvage therapy for relapsed/refractory B-NHL with rituximab?
Time of Update: 2022-11-01
Study results 01 Baseline characteristics of patientsA total of 15 patients with a median age of 48 years were included, of whom 9 (60%) had relapse and 6 (40%) were refractory to rituximab-based chemotherapy.
Poke "Read Original" to see moreThis study shows that CD20 CAR-T cells are feasible and effective in patients with rituximab-R/R CD20+B-NHL.
-
Acta haematol: Phase II study of azacitidine, vignitok clarke, and trametinib carrying RAS pathway-activating mutations in relapsed or refractory acute myeloid leukemia
Time of Update: 2022-10-31
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
